Omentin-1 Level in Psoriatic Patients Treated With Narrowband Ultraviolet B Phototherapy Versus Acitretin

Phase 4

Completed

• Conditions: Psoriasis
• Interventions: Radiation: Narrowband Ultraviolet B; Drug: Acitretin

• Registration Number: NCT05203354
• Lead Sponsor: Mahmoud Ahmed Ali Ahmed

Brief Summary

Studying the effects of Narrowband Ultraviolet B versus acitretin on psoriatic patients

Detailed Description

Compare the effects of Narrowband Ultraviolet B versus acitretin on serum Omentin-1 level in psoriatic patients as case control study by dividing patients into 3 groups: group 1 include patients receive Narrowband Ultraviolet B, group II includes patients receive acitretin (0.5-1 mg/day) and control group. The duration of this study about 3 months after receving those interventions.

Study Timeline

• Study Start: 2018-09-01
• Primary Completion: 2021-05-01
• Study Completion: 2021-08-15
• Study First Submitted: 2021-12-14
• Status Verified: 2022-01
• Study First Submitted QC: 2022-01-05
• Last Update Submitted: 2022-01-05
• Study First Posted: 2022-01-24
• Last Update Posted: 2022-01-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Patients of both sexes with psoriasis vulgaris.

Exclusion Criteria

• • Patients with history of malignancies, renal and liver diseases.

  • Patients received NB-UVB phototherapy in the last 6 months.
  • Patients treated with methotrexate or biologic agents and any systemic treatment of psoriasis.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
NB-UVB group	Narrowband Ultraviolet B	Patients who receive Narrowband ultraviolet B phototherapy
Acitretin group	Acitretin	Patients who receive acitretin

Primary Outcome Measures

Name	Time	Method
Decrease Omentin-1 serum level in both groups treated with NB-UVB and Acitretin	3 months	This outcome indicates potential role of Omentin-1 in psoriasis pathogenesis and its involvement in pathogenesis of obesity and related diseases as metabolic syndrome. So it will be concluded that high levels of this protein could be marker against obesity and related disorders including psoriasis. Omentin-1 can be valuable marker for psoriasis severity detected by its correlation with psoriasis area severity index (PASI) score and for evaluating the therapeutic outcomes

Secondary Outcome Measures

Name	Time	Method
Decrease PASI score in psoriatic patients	3 months	Decrease in PASI score in psoriatic patients after treatment with NB-UVB acitretin

Trial Locations

Locations (1)

Faculty of medicine - Aswan university; 🇪🇬 Aswan, Egypt